Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed

Year of Publication: 2020
Contained in: Emerging microbes & infections Vol. 9, No. 1 (2020), p. 727-732
All journal articles: Search for all articles in this journal
Language: English
Contributors: Lin, Ling | Author
Lu, Lianfeng
Cao, Wei
Li, Taisheng
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
IVIg
Journal Article
SARS-CoV-2
anticoagulation
pathogenesis
Additional Keywords: Animals
Antibodies, Viral
Anticoagulants
B-Lymphocytes
Betacoronavirus
Coronavirus Infections
Cytokines
Heparin, Low-Molecular-Weight
Humans
Immunoglobulins, Intravenous
Immunologic Factors
Influenza A Virus, H1N1 Subtype
Influenza, Human
Mice
Middle East Respiratory Syndrome Coronavirus
Pandemics
Pneumonia, Viral
SARS Virus
Severe Acute Respiratory Syndrome
T-Lymphocytes
ISSN: 2222-1751
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 07.04.2020
Date Revised 28.04.2020
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1080/22221751.2020.1746199
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04735nma a2200913 c 4500
001 NLM30866714X
003 DE-601
005 20200428214549.0
007 cr uuu---uuuuu
008 200330s2020 000 0 eng d
024 7 |a 10.1080/22221751.2020.1746199  |2 doi 
028 5 2 |a pubmed20n1182.xml 
035 |a (DE-599)NLM32196410 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Lin, Ling 
245 1 0 |a Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 07.04.2020 
500 |a Date Revised 28.04.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with droplets and contact as the main means of transmission. Since the first case appeared in Wuhan, China, in December 2019, the outbreak has gradually spread nationwide. Up to now, according to official data released by the Chinese health commission, the number of newly diagnosed patients has been declining, and the epidemic is gradually being controlled. Although most patients have mild symptoms and good prognosis after infection, some patients developed severe and die from multiple organ complications. The pathogenesis of SARS-CoV-2 infection in humans remains unclear. Immune function is a strong defense against invasive pathogens and there is currently no specific antiviral drug against the virus. This article reviews the immunological changes of coronaviruses like SARS, MERS and other viral pneumonia similar to SARS-CoV-2. Combined with the published literature, the potential pathogenesis of COVID-19 is inferred, and the treatment recommendations for giving high-doses intravenous immunoglobulin and low-molecular-weight heparin anticoagulant therapy to severe type patients are proposed 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Animals  |6 D000818 
653 2 |a Antibodies, Viral  |6 D000914  |a blood  |6 Q000097  |a immunology  |6 Q000276 
653 2 |a Anticoagulants  |6 D000925  |a therapeutic use  |6 Q000627 
653 2 |a B-Lymphocytes  |6 D001402  |a immunology  |6 Q000276 
653 2 |a Betacoronavirus  |6 D000073640  |a pathogenicity  |6 Q000472 
653 2 |a Coronavirus Infections  |6 D018352  |a drug therapy  |6 Q000188  |a *immunology  |6 Q000276  |a therapy  |6 Q000628  |a virology  |6 Q000821 
653 2 |a Cytokines  |6 D016207  |a immunology  |6 Q000276  |a metabolism  |6 Q000378 
653 2 |a Heparin, Low-Molecular-Weight  |6 D006495  |a therapeutic use  |6 Q000627 
653 2 |a Humans  |6 D006801 
653 2 |a Immunoglobulins, Intravenous  |6 D016756  |a therapeutic use  |6 Q000627 
653 2 |a Immunologic Factors  |6 D007155  |a therapeutic use  |6 Q000627 
653 2 |a Influenza A Virus, H1N1 Subtype  |6 D053118 
653 2 |a Influenza, Human  |6 D007251  |a immunology  |6 Q000276 
653 2 |a Mice  |6 D051379 
653 2 |a Middle East Respiratory Syndrome Coronavirus  |6 D065207  |a immunology  |6 Q000276 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a drug therapy  |6 Q000188  |a *immunology  |6 Q000276  |a therapy  |6 Q000628  |a virology  |6 Q000821 
653 2 |a SARS Virus  |6 D045473  |a immunology  |6 Q000276 
653 2 |a Severe Acute Respiratory Syndrome  |6 D045169  |a *immunology  |6 Q000276 
653 2 |a T-Lymphocytes  |6 D013601  |a immunology  |6 Q000276 
655 7 |a COVID-19  |2 gnd 
655 7 |a IVIg  |2 gnd 
655 7 |a SARS-CoV-2  |2 gnd 
655 7 |a anticoagulation  |2 gnd 
655 7 |a pathogenesis  |2 gnd 
655 7 |a Antibodies, Viral  |2 gnd 
655 7 |a Anticoagulants  |2 gnd 
655 7 |a Cytokines  |2 gnd 
655 7 |a Heparin, Low-Molecular-Weight  |2 gnd 
655 7 |a Immunoglobulins, Intravenous  |2 gnd 
655 7 |a Immunologic Factors  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a IVIg 
689 1 2 |a SARS-CoV-2 
689 1 3 |a anticoagulation 
689 1 4 |a pathogenesis 
689 1 |5 DE-601 
689 2 0 |a Antibodies, Viral 
689 2 1 |a Anticoagulants 
689 2 2 |a Cytokines 
689 2 3 |a Heparin, Low-Molecular-Weight 
689 2 4 |a Immunoglobulins, Intravenous 
689 2 5 |a Immunologic Factors 
689 2 |5 DE-601 
700 1 |a Lu, Lianfeng 
700 1 |a Cao, Wei 
700 1 |a Li, Taisheng 
773 0 8 |i in  |t Emerging microbes & infections  |g Vol. 9, No. 1 (2020), p. 727-732  |q 9:1<727-732  |w (DE-601)NLM249572478  |x 2222-1751 
856 4 1 |u http://dx.doi.org/10.1080/22221751.2020.1746199  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 9  |j 2020  |e 1  |b 27  |c 12  |h 727-732